H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-20 08:00
Regulatory News Service
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB
2025-02-05 07:46
Annual Report
English 6.4 MB
2025-02-05 07:46
Report Publication Announcement
English 2.9 KB
2025-02-05 07:46
Annual Report (ESEF)
English 13.1 MB
2025-02-05 07:24
Earnings Release
English 33.3 KB
2025-02-05 07:24
Earnings Release
English 443.0 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.